---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Administration"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Administration. Topics: Pharmaceutical form and route in the European Union paediatric investigation plan, Delivery into the cerebrospinal fluid, Procedure and care setting, Administration of the first dose given in the clinical program, and 1 further topic. 5 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/administration"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Administration

<a id="heading-2.1.2.10.2"></a>

## 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

### Pharmaceutical form and route in the European Union paediatric investigation plan

> “Pharmaceutical form(s): Solution for infusion Route(s) of administration: Intrathecal use”

Source: [EMA paediatric investigation plan decision (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232894-ema-decision-14-april-2025-agreement-paediatric-investigation-plan-granting-deferral-adeno-associated-viral-vector-serotype-9-containing-human-mecp2-gene_en.pdf-0)

<a id="topic-2.1.2.10.2-2"></a>

### Delivery into the cerebrospinal fluid

> “The vector is delivered directly to the cerebrospinal fluid via intrathecal administration, which facilitates optimal biodistribution and cell transduction within key regions of the CNS.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.1.2.10.2-3"></a>

### Procedure and care setting

> “We use intrathecal administration, which directly delivers our gene therapies to the cerebrospinal fluid to facilitate biodistribution and cell transduction within key regions of the CNS. The procedure is routinely performed in an outpatient setting, and compared to intravenous administration, it allows for a lower dose of the therapy.”

Source: [Taysha Gene Therapies our science page](https://tayshagtx.com/our-science/)

> “Leads to widespread and consistent biodistribution across the brain and spinal cord using a routine, minimally invasive procedure with potential for outpatient administration”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-2.1.2.10.2-4"></a>

### Administration of the first dose given in the clinical program

> “Taysha-102 was injected intrathecally in the lumbar spine, with general anesthesia.”
> “The Participant was discharged on Day 1.”

Source: [Rossignol et al. (2023)](https://tayshagtx.com/wp-content/uploads/Early-safety-and-efficacy-observations-following-the-first-use-of-TSHA-102-gene-therapy-in-a-patient-with-Rett-Syndrome.pdf)

<a id="topic-2.1.2.10.2-5"></a>

### Positioning and monitoring after dosing

> “Patients were placed in Trendelenburg position post-dosing. Regular safety monitoring includes clinical and laboratory evaluations.”

Source: [Rossignol et al. (2024b)](https://tayshagtx.com/wp-content/uploads/TSHA-102-gene-therapy-for-Rett-syndrome-First-cohort-data-from-the-REVEAL-Adolescent-Adult-and-Pediatric-studies.pdf)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
